"Factor VIIa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
| Descriptor ID |
D015942
|
| MeSH Number(s) |
D08.811.277.656.300.760.300 D08.811.277.656.959.350.300 D12.776.124.125.325.300 D23.119.325.300
|
| Concept/Terms |
Factor VIIa- Factor VIIa
- Coagulation Factor VIIa
- Factor VIIa, Coagulation
- Blood Coagulation Factor VII, Activated
- Factor VII, Activated
- Activated Factor VII
- Factor 7A
- Factor Seven A
|
Below are MeSH descriptors whose meaning is more general than "Factor VIIa".
Below are MeSH descriptors whose meaning is more specific than "Factor VIIa".
This graph shows the total number of publications written about "Factor VIIa" by people in this website by year, and whether "Factor VIIa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 3 | 1 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor VIIa" by people in Profiles.
-
Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. Int J Stroke. 2022 08; 17(7):806-809.
-
Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials. JAMA Neurol. 2019 12 01; 76(12):1493-1501.
-
Porcine blood and surrogate markers do not prove benefit of aDabi-Fab. Crit Care. 2014 Jun 17; 18(3):435.
-
Timing of factor VIIa in liver transplantation impacts cost and clinical outcomes. Pharmacotherapy. 2013 May; 33(5):483-8.
-
Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila). 2012 Jul-Aug; 7(4):229-41.
-
Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2012 May; 143(5):1069-76.
-
The use of activated recombinant factor VII in a patient with fulminant hepatic failure requiring placement of an intracranial pressure monitor. Ann Pharmacother. 2011 Nov; 45(11):e60.
-
Clinical usefulness of recombinant activated factor VII in patients with liver failure undergoing invasive procedures. Ann Pharmacother. 2011 Nov; 45(11):1433-8.
-
Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. J Thorac Cardiovasc Surg. 2011 Jun; 141(6):1469-77.e2.
-
Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery. Ann Thorac Surg. 2008 May; 85(5):1669-76; discussion 1676-7.